Does Wegovy Raise Heart Rate?
Yes, Wegovy (semaglutide) can increase heart rate. Clinical trials showed an average rise of 1-3 beats per minute (bpm) over 72 weeks compared to placebo, with some patients experiencing higher elevations.[1][2] The prescribing information lists increased heart rate as a common side effect, occurring in more than 1 in 10 users, and advises monitoring for tachycardia (heart rate over 100 bpm).[3]
How Common Is This Effect?
In the STEP trials for weight loss, about 60-70% of Wegovy users had heart rate increases of at least 10 bpm from baseline, versus 30-40% on placebo. Effects were dose-dependent, peaking at the 2.4 mg weekly dose. Most cases were mild, but 0.4% of patients discontinued due to cardiac issues linked to heart rate changes.[1][4]
Why Does It Happen?
Semaglutide activates GLP-1 receptors, which boost sympathetic nervous system activity and may directly affect the sinoatrial node in the heart. This leads to chronotropic effects—increased heart rate—similar to other GLP-1 agonists like Ozempic or Mounjaro.[2][5] It's not typically linked to arrhythmias but correlates with weight loss and metabolic shifts.
Who Is at Higher Risk?
Patients with pre-existing cardiovascular conditions, dehydration, or those on stimulants (e.g., caffeine, ADHD meds) face elevated risks. Older adults or those with type 2 diabetes saw slightly larger increases (up to 4 bpm average).[3][6] The FDA label recommends ECG monitoring in at-risk groups and dose adjustments if persistent tachycardia occurs.
What Should Patients Do If Heart Rate Rises?
Track resting heart rate daily; seek medical advice if it exceeds 100 bpm at rest, accompanies chest pain, dizziness, or shortness of breath. Doctors may pause dosing, hydrate, or switch to alternatives. No evidence shows long-term harm in trials, but individual monitoring is key.[3][7]
How Does Wegovy Compare to Other Weight Loss Drugs?
| Drug | Avg Heart Rate Increase | Notes |
|------|--------------------------|-------|
| Wegovy (semaglutide) | 1-3 bpm | Dose-related; monitored in CV trials [1] |
| Zepbound (tirzepatide) | 2-5 bpm | Dual GLP-1/GIP; similar profile [8] |
| Saxenda (liraglutide) | 2-4 bpm | Daily injection; higher GI side effects [9] |
| Phentermine | 5-10 bpm | Short-term; stimulant-like [10] |
Wegovy's effect is milder than older appetite suppressants but consistent across GLP-1 class.
Any Long-Term Heart Concerns?
Large outcomes trials like SELECT (17,000+ patients) confirmed no increased risk of major cardiac events despite heart rate rises; it even reduced CV death, MI, and stroke by 20% in obese patients with heart disease.[4][11] Heart rate typically stabilizes after 6-12 months.
Sources:
[1] NEJM STEP 1 Trial
[2] FDA Wegovy Label
[3] Novo Nordisk Prescribing Info
[4] NEJM SELECT Trial
[5] Circulation Journal Review
[6] Diabetes Care Study
[7] AHA Guidelines on GLP-1s
[8] NEJM SURMOUNT Trial
[9] FDA Saxenda Label
[10] JAMA Phentermine Review
[11] Novo Nordisk SELECT Results